Evidence map›Paper›PMID 32151039›Full record

ArticleInternational journal of environmental research and public health2020

Affordability Assessment from a Static to Dynamic Concept: A Scenario-Based Assessment of Cardiovascular Medicines.

Leila Zarei, Iman Karimzadeh, Najmeh Moradi, Payam Peymani, Sara Asadi, Zaheer-Ud-Din Babar

Open access · goldAbstract read
In one paragraph

Article in International journal of environmental research and public health, 2020. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 4 papers.

0numbers the graph read from it
0cells of the map it votes in
4citing papers in PubMed
1.8field-weighted citation impact, top 9% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

4 citing papers in PubMed, 8 citations in OpenAlex.

  1. Article
  2. Article
  3. Article
  4. Utilization, Cost, and Affordability of Antihypertensive Therapy in Bulgaria.Iranian journal of pharmaceutical research : IJPR · 2021
    Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

6 authors at 3 institutions in 3 countries.

Leila ZareiPharmacoeconomics and Pharma Management, Health Policy Research Center, Institute of Heath, Shiraz University of Medical Sciences, Shiraz, Fars, Iran.
Iman KarimzadehClinical Pharmacy, School of Pharmacy, Shiraz University of Medical Sciences, Shiraz, Fars, Iran.
Najmeh MoradiPharmacoeconomics and Pharma Management, Health Management and Economics Research Centre, Iran University of Medical Sciences, Tehran, Iran.
Payam PeymaniPharmacoepidemiology, Health Policy Research Center, Institute of Heath,Shiraz University of Medical Sciences, Shiraz, Fars, Iran.
Sara AsadiClinical Pharmacy, Shiraz University of Medical Sciences, Shiraz, Fars, Iran.
Zaheer-Ud-Din BabarMedicines and Healthcare, Department of Pharmacy, University of Huddersfield, Queensgate,Huddersfield HD1 3DH, UK.
Shiraz University of Medical Sciences · IRIran University of Medical Sciences · IRUniversity of Huddersfield · GB

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

The out-of-pocket payments for prescription medications can impose a financial burden on patients from low- and middle- incomes and who suffer from chronic diseases. The present study aims at evaluating the affordability of cardiovascular disease (CVD) medication in Iran. This includes measuring affordability through World Health Organization/Health Action International (WHO/HAI) methodology. In this method, affordability is characterized as the number of days' wages of the lowest-paid unskilled government worker. The different medication therapy scenarios are defined in mono-and combination therapy approaches. This method adds on to WHO/HAI methodology to discover new approaches to affordability assessments. The results show the differences in the medicines affordability when different approaches are used in mono-and combination therapy between 6 main sub-therapeutic groups of CVD. It indicates the medicine affordability is not a static concept and it changes dynamically between CVD therapeutic subgroups when it used alone or in combination with other medicines regarding patients' characteristics and medical conditions. Hypertension and anti-arrhythmia therapeutic groups had the most non-affordability and hyperlipidemia had the most affordable medicines. Therefore, affordability can be considered as a dynamic concept, which not only affected by the medicine price but significantly affected by a patient's characteristics, the number of medical conditions, and insurance coverage.

Indexed as

Cardiovascular AgentsCosts and Cost AnalysisHealth Services AccessibilityCross-Sectional StudiesDrugs, EssentialHumansIranWorld Health OrganizationCardiovascular AgentsDrugs, Essentialaffordabilitycardiovascular diseasehealth care systemmedication costmiddle-income countriesscenario-based assessment

Identifiers

PMID32151039
PMCPMC7084506
OpenAlexW3010284508

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.